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2 tOBJECTIVES This study sought to determine whether outcomes for transfemoral (TF) transcatheter aortic valve
replacement (TAVR) differ between the randomized controlled trial (RCT) and the subsequent NRCA (Nonrandomized
Continued Access) registry of the PARTNER (Placement of AoRTic TraNscathetER Valves) trial.
BACKGROUND The PARTNER RCT demonstrated that TAVR with the Edwards Sapien valve (Edwards Lifesciences,
Irvine, California) is noninferior to surgery in high-risk patients and superior to standard therapy for inoperable patients.
METHODS The inclusion and exclusion criteria, data collection, monitoring, and core laboratories were the same for the
RCT and NRCA registry. Baseline characteristics, procedural results, and 1-year outcomes were compared between
patients undergoing TF-TAVR as part of the RCT and as part of the NRCA registry.
RESULTS In the RCT, 415 patients underwent TF-TAVR, whereas in the NRCA, 1,023 patients did. At 30 days, death,
cardiac death, stroke, and transient ischemic attacks were not different in the NRCA registry than in the RCT. Major
vascular complications (8.0% vs. 15.7%, p < 0.0001) and major bleeding (6.8% vs. 15.3%, p < 0.0001) were signiﬁ-
cantly lower in the NRCA registry. At 1 year, death rates were signiﬁcantly lower in the NRCA cohort (19.0% vs. 25.3%,
p ¼ 0.009) and cardiac death tended to be lower (8.4% vs. 11.1%, p ¼ 0.12). Stroke or transient ischemic attack
(6.2% vs. 8.7%, p ¼ 0.10) and stroke alone (5.0% vs. 7.1%, p ¼ 0.13) also tended to be lower.
CONCLUSIONS The large NRCA registry demonstrates further improvement in procedural and longer-term outcomes
after TF-TAVR when compared with the favorable results from the PARTNER RCT. (THE PARTNER TRIAL: Placement of
AoRTic TraNscathetER Valve Trial; NCT00530894) (J Am Coll Cardiol Intv 2014;7:1245–51) © 2014 by the American
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1246T he PARTNER (Placement of AoRTicTraNscathetER Valves) randomizedcontrolled trial (RCT) demonstrated
that transcatheter aortic valve replacement
(TAVR) is superior to medical therapy in
inoperable patients with severe, symptom-
atic aortic stenosis (PARTNER 1B) and nonin-
ferior to surgical aortic valve replacement in
patients who are at high risk for complica-tions with traditional surgery (PARTNER 1A) (1–4).
The PARTNER trial represented the ﬁrst experience
with TAVR for most of the participating investigators,
primarily using an early generation delivery system
from the transfemoral (TF) approach. Following
completion of the randomized portions of the PART-
NER trial, the U.S. Food and Drug Administration
allowed the creation of the NRCA (NonrandomizedSEE PAGE 1252Continued Access) registry, which includes >1,000
patients with a newer generation TF delivery system
and with greater availability to a transapical
approach. The objective of this study is to determine
whether outcomes differ between the RCT and the
subsequent NRCA registry in patients who underwent
TF-TAVR.
METHODS
PATIENT POPULATION. Patients included in the RCT
and NRCA registry were those with severe, symp-
tomatic aortic stenosis who were either high-risk
candidates for surgical aortic valve replacement or
inoperable. The inclusion and exclusion criteria have
been reported previously (1,2). Brieﬂy, patients had to
have severe aortic stenosis, deﬁned as an aortic valve
area <0.8 cm2, plus either a mean gradient across the
aortic valve $40 mm Hg or a peak velocity across the
valve of $4 m/s on the basis of echocardiographic
evaluation, and with symptoms consistent with Newntiﬁc Corporation, Edwards Lifesciences, Medtronic, Siemens, St.
t for Edwards Lifesciences, St. Jude Medical, and Siemens. Dr. Br
and St. Jude Medical; and owns equity in The Heart Hospital Bay
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received April 30, 2014; accepted May 8, 2014.York Heart Association Functional classiﬁcation $II.
The deﬁnition of high risk was on the basis of a So-
ciety of Thoracic Surgery (STS) predicted operative
mortality $8% and/or an estimated risk of death
>15% at 30 days as assessed by the participating site’s
cardiac surgeons (5,6). Inoperability was on the basis
of a >50% predicted risk of death or serious irre-
versible condition at 30 days after surgery as assessed
by the participating site’s cardiac surgeons. Every
case was presented on a web-based conference call in
order to receive approval by the executive committee
of the study. Major exclusion criteria were a bicuspid
aortic valve, coronary disease requiring revasculari-
zation, percutaneous coronary intervention with-
in the past month, left ventricular ejection fraction
<20%, or severe mitral regurgitation.
STUDY DEVICE AND PROCEDURE. The TF-TAVR
procedure has been previously described (7). In the
randomized trial and the NRCA registry, a 22-F sheath
was inserted for a 23-mm Edwards Sapien valve
(Edwards Lifesciences, Irvine, California) and a 24-F
sheath for a 26-mm valve. In the majority (>85%) of
patients in the randomized trial, the valve was
delivered with the RetroFlex 1 or 2 delivery systems
(Edwards Lifesciences), whereas in the NRCA regis-
try, the RetroFlex 3 delivery system was used for all
patients (8,9). The RetroFlex 3 system allowed for
easier crossing of the native valve due to changes in
the nose cone of the delivery system and for more
predictable deployment, with less movement of the
valve during balloon inﬂation. Patients received
aspirin indeﬁnitely and clopidogrel for 6 months
following the procedure.
STUDY DESIGN. Details regarding the study design
have been reported previously (1,2). The PARTNER
1B trial randomized inoperable patients to either
TF-TAVR or medical therapy. The PARTNER 1A trial
randomized high-risk patients with adequate femoral
access to either TF-TAVR or open surgical aorticJude Medical, and W. L. Gore and Associates; and is
own has received grants from Edwards Lifesciences,
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1247valve replacement. Those without TF access were
randomized to transapical TAVR or to open surgical
aortic valve replacement. The NRCA registry included
patients who were either inoperable or high risk and
assigned them to TF-TAVR if their access was
adequate. If not, they underwent transapical TAVR.
For this study, patients were followed during the index
hospitalization and at 30 days, 6months, and 1 year. All
events were adjudicated by a clinical events commit-
tee. Independent core laboratories analyzed all elec-
trocardiograms and echocardiograms (10). All patients
provided written informed consent and the study was
approved by the institutional review board at each
participating site.
STATISTICAL ANALYSIS. Patients enrolled in the
RCT who underwent TF-TAVR were compared with
patients in the NRCA registry who received TF-TAVR.
The analyses were performed on an as-treated basis.
Continuous variables are presented as a mean  SD
and compared using the Student t-test. Categorical
variables were compared using chi-square or Fisher
exact test. Event rates are reported as Kaplan-Meier
estimates and were compared with the use of the
log-rank test. A 2-sided alpha level of 0.05 was used
for all superiority testing. All statistical analyses were
performed with the use of SAS software (version 9.2,
SAS Institute, Cary, North Carolina).FIGURE 1 Study Flowchart
Flowchart depicting the distribution and numbers of patients in the rando
Access) registry arm. CEC ¼ Clinical Events Committee; PARTNER ¼ Place
aortic valve replacement; TAVR ¼ transcatheter aortic valve replacemenRESULTS
Patients were enrolled in the RCT from 27 eligible
sites between May 1, 2007, and August 1, 2009,
whereas patients were enrolled in the NRCA from 27
eligible sites between September 2009 and January
2012. The study ﬂowchart is displayed in Figure 1. Of
the 519 patients undergoing TAVR in the RCT, 415
received TF-TAVR, which represented 80% of all
TAVR cases. Of the 2,014 patients included in the
NRCA registry, 1,039 were assigned to TF-TAVR,
which represented 52% of all TAVR cases. Of the
1,039 patients assigned to TF-TAVR, 1,023 actually
underwent the procedure and are included in this
analysis; of the other remaining patients, they were
immediately converted to a transapical approach,
underwent the procedure at a later date, and/or never
received a valve. Twenty-seven sites participated in
both the RCT and the NRCA registry. During the RCT,
the median enrollment was 8 patients per site with a
mean of 15 patients per site. During the NRCA, the
median enrollment was 34 patients per site with a
mean of 38 patients per site.
The baseline characteristics of the 2 groups are
displayed in Table 1. The NRCA group was older,
but had a lower STS score and logistic Euro-
SCORE (European System for Cardiac Operative Risk
Evaluation). A greater percent had received amized controlled trial (RCT) and the NRCA (Nonrandomized Continued
ment of Aortic Transcatheter Valve; TA ¼ transapical; SAVR ¼ surgical
t; TF ¼ transfemoral.
TABLE 1 Baseline Characteristics
NRCA TF-TAVR
(n ¼ 1,023)
RCT TF-TAVR
(n ¼ 415) p Value
Age, yrs 84.78  7.72 83.57  7.59 0.007
Male 579/1,023 (56.6) 224/415 (54.0) 0.36
Society of Thoracic Surgeons score 10.86  3.73 11.58  4.50 0.004
Logistic EuroSCORE 24.25  15.11 28.14  16.94 <0.0001
New York Heart Association functional class
III 487/1,023 (47.6) 187/415 (45.1) 0.38
IV 494/1,023 (48.3) 203/415 (48.9) 0.83
Coronary artery disease 771/1,021 (75.5) 300/415 (72.3) 0.20
Previous myocardial infarction 234/1,013 (23.1) 97/412 (23.5) 0.86
Previous CABG 378/1,020 (37.1) 154/415 (37.1) 0.99
Previous PCI 387/1,021 (37.9) 128/413 (31.0) 0.01
Previous balloon aortic valvuloplasty 244/1,013 (24.1) 58/415 (14.0) <0.0001
Cerebral vascular disease 210/1,006 (20.9) 104/398 (26.1) 0.03
Peripheral vascular disease 276/1,008 (27.4) 138/412 (33.5) 0.02
COPD
Any 439/1,023 (42.9) 182/415 (43.9) 0.74
Oxygen-dependent 115/1,023 (11.2) 63/415 (15.2) 0.04
Creatinine level >2 mg/dl, or 177 mmol/l 150/1,020 (14.7) 84/414 (20.3) 0.010
Major arrhythmia 549/1,020 (53.8) 202/415 (48.7) 0.08
Permanent pacemaker 229/1,021 (22.4) 83/415 (20.0) 0.31
Pulmonary hypertension 393/1,021 (38.5) 127/303 (41.9) 0.28
Frail condition 132/1,021 (12.9) 51/301 (16.9) 0.08
Aortic-valve area, cm2 0.66  0.19 0.65  0.19 0.44
Aortic-valve mean gradient, mm Hg 44.51  14.46 43.68  14.89 0.34
Left ventricular ejection fraction, % 52.5  13.5 53.3  12.8 0.45
Moderate or severe mitral regurgitation 188/973 (19.3) 64/385 (16.6) 0.25
Values are mean  SD or n/N (%).
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European
System for Cardiac Operative Risk Evaluation; NRCA ¼ Nonrandomized Continued Access registry;
PCI ¼ percutaneous coronary intervention; RCT ¼ randomized controlled trial; TAVR ¼ transcatheter aortic valve
replacement; TF ¼ transfemoral.
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1248previous balloon aortic valvuloplasty, but fewer had
cerebrovascular disease, peripheral arterial disease,
renal disease, or oxygen-dependent chronic obstruc-
tive pulmonary disease. The baseline echocardiogra-
phy data were similar between the 2 groups with
no signiﬁcant difference in the aortic valve areaTABLE 2 Procedural Characteristics
NRCA TF-TAVR
(n ¼ 1,023)
RCT TF-TAVR
(n ¼ 415) p Value
Surgical cutdown, % 49.1 76.8 <0.0001
Total procedure time, min 117.64  56.91 145.10  82.37 <0.0001
Contrast use, ml 140.77  162.53 141.21  86.64 0.95
Post-dilation 9.4 36.7 <0.0001
Valve sizing
23 mm, % 52.7 51.0 0.56
26 mm, % 47.2 49.0 0.54
Values are % or median  SD.
Abbreviations as in Table 1.(0.66  0.19 cm2 vs. 0.65  0.19 cm2, p ¼ 0.44), mean
gradient across the aortic valve (44.5  14.5 mm Hg
vs. 43.7  14.9 mm Hg, p ¼ 0.34), or left ventricular
ejection fraction (52.1  13.2% vs. 52.7  13.7%,
p ¼ 0.48) in the NRCA and RCT patients, respectively.
The procedural differences between the 2 groups
are displayed in Table 2. In the NRCA registry, fewer
patients underwent surgical cutdown for arterial
access (49.1% vs. 76.8%, p < 0.0001), fewer received
balloon post-dilation after valve deployment (9.4%
vs. 36.7%, p < 0.0001), and procedure duration was
signiﬁcantly shorter (117.6  57.0 min vs. 145.1 
82.3 min, p < 0.0001). There was no signiﬁcant dif-
ference in the rate of moderate or severe paravalvular
regurgitation between the 2 cohorts (11.3% vs 10.8%,
p ¼ 0.78), as displayed in Figure 2.
The 30-day outcomes are displayed in Table 3.
Adverse events, including death, cardiac death,
stroke, and transient ischemic attacks were numeri-
cally less in the NRCA registry, but not signiﬁcantly
different than in the RCT. Vascular complications
(8.0% vs. 15.7%, p < 0.0001) and major bleeding
(6.8% vs. 15.3%, p < 0.0001) were signiﬁcantly lower
in the NRCA registry versus the RCT.
The 1-year outcomes are also displayed in Table 3.
Death rates were signiﬁcantly lower in the NRCA
cohort than in the RCT (19.0% vs. 25.3%, p ¼ 0.009)
and cardiac death tended to be lower (8.4% vs. 11.1%,
p ¼ 0.12). Stroke or transient ischemic attack (6.2%
vs. 8.7%, p ¼ 0.10) and stroke alone (5.0% vs. 7.1%,
p ¼ 0.13), also tended to be lower. The Kaplan-Meier
curves for death are shown in Figure 3.
DISCUSSION
The main ﬁnding in this study is that outcomes in the
NRCA registry, including over 1,000 consecutive
TF-TAVR patients were equivalent or superior to
those of the RCT. In particular, major vascular and
bleeding complications at 30 days were signiﬁcantly
lower in the NRCA cohort. The 1-year mortality in the
NRCA group was signiﬁcantly lower than in the RCT
population (19.0% vs. 25.3%, p ¼ 0.009), whereas
rates of neurologic events trended lower.
There are a number of factors that might contribute
to the improved outcomes in the NRCA group.
Although this group was signiﬁcantly older, fewer
patients had cerebrovascular disease, peripheral
arterial disease, renal disease, or oxygen-dependent
chronic obstructive pulmonary disease; the mean
STS and mean logistic EuroSCORE in the NRCA reg-
istry patients were signiﬁcantly lower. These differ-
ences in baseline characteristics may be explained in
part by improved patient selection as a result of
FIGURE 2 Paravalvular Regurgitation
Chart demonstrating the degree of paravalvular regurgitation at 30 days, 6 months, and
1 year in each group. NS ¼ not signiﬁcant; other abbreviations as in Figure 1.
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1249investigator experience and in part by increased
availability of the transapical access approach in the
NRCA group (11). These factors likely contributed to
the dramatic reduction in vascular and bleeding
complications, both of which decreased by >50%, and
likely translated into the signiﬁcant reduction in 1-
year mortality seen in the NRCA patients (12,13).
Another important ﬁnding in this study is that
with increased experience, procedural times and
outcomes improved. In the RCT, the mean number
of patients treated per site was only 15, whereas in
the NRCA portion, it increased to 38 patients per
site. In conjunction with this change, procedure time
decreased by a man of 28 min per case or roughly
20%. Interestingly, the rate of post-dilation of the
Sapien valve after deployment was signiﬁcantly
lower in the NRCA patients, yet the degree of para-
valvular regurgitation was no different than that of
the RCT. This ﬁnding may be explained by enhanced
operator experience with valve sizing and by the
increased availability of the transapical approach,
resulting in less need to deploy a 23-mm valve
because of femoral or iliac vessel size limitations. In
addition, reports were published after completion ofTABLE 3 Clinical Outcomes at 30 Days and 1 Year
30 Days
NRCA TF-TAVR
(n ¼ 1,023)
RCT TF-TAV
(n ¼ 415)
Death
From any cause 44 (4.3) 20 (4.8)
From cardiac causes 33 (3.2) 18 (4.3)
Repeat hospitalization 70 (7.1) 26 (6.5)
Death or repeat hospitalization 114 (11.1) 45 (10.8
Stroke or transient ischemic attack
Either 42 (4.2) 23 (5.6)
Transient ischemic attack 5 (0.5) 3 (0.7)
Stroke
Minor 13 (1.3) 5 (1.2)
Major 24 (2.4) 15 (3.6)
Death from any cause or major stroke 64 (6.3) 31 (7.5)
Myocardial infarction 6 (0.6) 0 (0)
Vascular complication
Any 160 (15.7) 115 (27.8
Major 82 (8.0) 65 (15.7)
Renal failure—dialysis required 16 (1.6) 11 (2.7)
Hemorrhagic event
Minor bleeding 9 (0.9) 31 (7.5)
Major bleeding 69 (6.8) 63 (15.3)
Embolic event 18 (1.8) 4 (1.0)
Bradyarrhythmic event 69 (6.8) 18 (4.4)
Unplanned arterial vascular procedure 132 (12.9) 91 (21.9)
Values are n (%).
Abbreviations as in Table 1.the RCT, suggesting higher rates of neurologic
events when post-dilation was performed after
TAVR, which may have affected post-dilation rates
in the NRCA (14,15). Finally, changes in the delivery1 Year
R
p Value
NRCA TF-TAVR
(n ¼ 1,023)
RCT TF-TAVR
(n ¼ 415) p Value
0.68 192 (19.0) 105 (25.3) 0.009
0.32 81 (8.4) 44 (11.1) 0.12
0.67 185 (19.6) 71 (18.9) 0.68
) 0.84 321 (31.7) 148 (35.7) 0.20
0.24 60 (6.2) 34 (8.7) 0.10
0.59 12 (1.3) 6 (1.6) 0.66
0.91 14 (1.4) 7 (1.8) 0.66
0.20 35 (3.6) 21 (5.3) 0.14
0.41 209 (20.7) 112 (27.0) 0.009
0.12 14 (1.5) 1 (0.3) 0.059
) <0.0001 169 (16.6) 115 (27.8) <0.0001
<0.0001 85 (8.4) 65 (15.7) <0.0001
0.17 34 (3.6) 15 (3.7) 0.76
<0.0001 12 (1.2) 36 (9.0) <0.0001
<0.0001 125 (12.9) 79 (19.6) 0.0004
0.26 19 (1.9) 5 (1.2) 0.38
0.08 80 (8.1) 22 (5.5) 0.09
<0.0001 141 (13.9) 95 (23.1) <0.0001
FIGURE 3 Kaplan-Meier Curves for Death
The Kaplan-Meier survival curves for each group. CI ¼ conﬁdence interval;
HR ¼ hazard ratio; other abbreviations as in Figure 1.
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1250system from the RetroFlex 1 and 2 systems used in
the RCT to the RetroFlex 3 system used in the NRCA
may have allowed for more rapid crossing of the
native valve and for more precise positioning during
deployment of the valve. These differences may
have affected the time of the procedure and the
complication rate.
The NRCA registry represents the largest group of
TF-TAVR patients in the United States with at least
1-year follow-up and the largest registry worldwide
with core laboratory analyses and centralized adju-
dication of clinical events. The 81.1% 1-year survival
in this cohort is identical to what was reported in
the 463 TF-TAVR patients in the U.K. SOURCE
(Sapien Aortic Bioprosthesis European Outcome)
registry and similar to the 78.3% 1-year survival in
the 2,361 TF-patients in the FRANCE 2 registry(16,17). The STS/ACC TVT (Society of Thoracic Sur-
geons/American College of Cardiology Transcatheter
Valve Therapy) registry recently reported 30-day
outcomes in 2,176 U.S. patients receiving TF-TAVR
and found a 4.9% mortality, which is similar to
our data from the NRCA registry (18). However, the
median STS predicted operative mortality in the
STS/ACC TVT registry was 7%, suggesting that this
cohort was lower risk than that of the NRCA regis-
try. One-year data from the STS/ACC TVT registry
are not yet reported.
STUDY LIMITATIONS. Limitations include the differ-
ences in utilization of the transapical approach in the
RCT and the NRCA registry and the temporal differ-
ence in enrollment in the 2 cohorts. The increased use
of transapical TAVR in the NRCA may have led to a
lower risk TF-TAVR patient population with fewer
comorbidities, thereby resulting in improved out-
comes in this group. A separate report details the
results after transapical TAVR (19). Furthermore, the
temporal difference makes the comparison of out-
comes challenging because of differences in operator
experience and enhancements in device technology,
all of which likely contributed to varying degrees.
CONCLUSIONS
In the NRCA registry of the PARTNER trial, which
included over 1,000 patients undergoing TF-TAVR,
procedural complications and 1-year outcomes,
including death, were signiﬁcantly reduced compared
with those of the RCT. The improved results may
reﬂect superior patient selection, advances in device
technology, and enhanced procedural skills.
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